CHA₂DS₂-VA Score Calculator

CHA₂DS₂-VA Score: Complete Clinical Guide

What changed in ESC 2024, how to calculate the score, annual stroke risk percentages, anticoagulation thresholds and DOAC selection — with ESC 2024, Lancet, PMC and Eur Heart J references

What Is the CHA₂DS₂-VA Score?

The CHA₂DS₂-VA score is a clinical prediction rule used to estimate the annual risk of thromboembolic stroke in patients with non-valvular atrial fibrillation (AF). It is used to guide the decision of whether to initiate oral anticoagulation therapy — the most important intervention available to prevent AF-related stroke, which accounts for approximately 20–30% of all ischaemic strokes globally.

The score was formally adopted in the 2024 ESC Guidelines for the Management of Atrial Fibrillation (Van Gelder et al., Eur Heart J 2024) as an updated, simplified version of the widely-used CHA₂DS₂-VASc score — with one critical change: female sex has been removed as a risk variable.

⚡ What Changed in ESC 2024 — CHA₂DS₂-VA vs CHA₂DS₂-VASc

Key change: Female sex (the "Sc" component) has been REMOVED from the score.

The ESC 2024 guidelines state: "The inclusion of gender complicates clinical practice both for healthcare professionals and patients. It also omits individuals who identify as non-binary, transgender, or are undergoing sex hormone therapy."

The evidence behind this change comes from multiple large studies. A landmark nationwide UK study of over 1 million primary care patients (Yoshimura et al., Europace 2024) demonstrated that removing female sex from the score did not compromise its ability to discriminate thromboembolic events. A Finnish national registry study of AF patients confirmed that the CHA₂DS₂-VA score showed comparable predictive accuracy to CHA₂DS₂-VASc across different ethnicities and socioeconomic groups (Teppo et al., Lancet Reg Health Eur 2024).

Component	CHA₂DS₂-VASc (old)	CHA₂DS₂-VA (ESC 2024)
C — Congestive Heart Failure	+1	+1
H — Hypertension	+1	+1
A₂ — Age ≥75	+2	+2
D — Diabetes Mellitus	+1	+1
S₂ — Prior Stroke / TIA / TE	+2	+2
V — Vascular Disease	+1	+1
A — Age 65–74	+1	+1
Sc — Female Sex	+1	REMOVED ✓
Maximum Score	9	9

Annual Stroke Risk by Score

Score	Annual Stroke Risk	Risk Level	ESC 2024 Recommendation
0	~0%	Very Low	No anticoagulation recommended
1	~1.3%	Low–Moderate	Consider OAC (Class IIa) — individualised decision
2	~2.2%	Moderate–High	OAC recommended (Class I)
3	~3.2%	High	OAC strongly recommended
4	~4.0%	High	OAC strongly recommended
5	~6.7%	High	OAC strongly recommended
6	~9.8%	Very High	OAC strongly recommended
≥7	>10%	Very High	OAC essential; consider referral

Stroke rates from Lip GYH et al. Chest 2010; ESC 2024 Guidelines. OAC = oral anticoagulant. Rates in non-anticoagulated patients.

Preferred DOACs in Non-Valvular AF (ESC 2024 — Class I)

When anticoagulation is indicated, ESC 2024 strongly recommends Direct Oral Anticoagulants (DOACs) over Vitamin K Antagonists (warfarin) for non-valvular AF, unless contraindicated. DOACs offer comparable or superior efficacy with a significantly lower risk of intracranial haemorrhage.

DOAC	Standard Dose	Reduced Dose	Renal Monitoring
Apixaban	5mg BD	2.5mg BD if ≥2: age ≥80, weight ≤60kg, Cr ≥133	Annually
Rivaroxaban	20mg OD with evening meal	15mg OD if CrCl 15–49	Annually
Dabigatran	150mg BD	110mg BD if age ≥80 or high bleeding risk	Every 6–12 months
Edoxaban	60mg OD	30mg OD if CrCl 15–50, wt ≤60kg, or P-gp inhibitor	Annually

Always verify with current BNF / drug SPC. DOACs are contraindicated in mechanical heart valves and moderate-severe mitral stenosis — use warfarin in these cases.

🚫 Anticoagulation Contraindications

Active major bleeding
Recent haemorrhagic stroke (<1–3 months)
Severe thrombocytopaenia (<50 × 10⁹/L)
Severe liver disease / coagulopathy
Pregnancy (use LMWH instead)

💊 Use Warfarin NOT DOAC When:

Mechanical prosthetic heart valve
Moderate-severe rheumatic mitral stenosis
CrCl <15 mL/min (DOAC data limited)
Antiphospholipid syndrome (triple positive)

Try MedDraftPro's Other Clinical Tools

Creatinine Clearance (for DOAC dose checking), Drug Dosage Calculator, Pediatric Dose — all free.

Explore All Tools →

References

Van Gelder IC, Rienstra M, Bunting KV et al. 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2024;45(36):3314-3414. doi:10.1093/eurheartj/ehae176
Yoshimura H, Providencia R, Finan C et al. Refining the CHA₂DS₂VASc risk stratification scheme: shall we drop the sex category criterion? Europace. 2024. PMC11574618.
Teppo K, Lip GYH, Airaksinen KEJ et al. Comparing CHA₂DS₂-VA and CHA₂DS₂-VASc scores for stroke risk stratification. Lancet Reg Health Eur. 2024;43:100967.
Lip GYH, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation. Chest. 2010;137(2):263-272.
Camm AJ, Kirchhof P, Lip GYH et al. ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31:2369-2429.
January CT, Wann LS, Calkins H et al. 2019 AHA/ACC/HRS focused update of the 2014 guideline for management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74(1):104-132.
Lip GYH, Teppo K, Nielsen PB. CHA₂DS₂-VASc or a non-sex score (CHA₂DS₂-VA) for stroke risk prediction in AF. Eur Heart J. 2024;45:3718-20.
NICE guideline NG196. Atrial fibrillation: diagnosis and management. Updated June 2024.

⚠️ Medical Disclaimer: This calculator is for clinical decision support and educational purposes only. Anticoagulation decisions must be made by a qualified clinician taking into account the full clinical picture, individual bleeding risk, patient preferences, and current local guidelines. This tool does not replace clinical assessment.